Literature DB >> 21969126

Molecular aspects of renal cell carcinoma: a review.

Hari Koul, Jung-Sik Huh, Kyle O Rove, Luiza Crompton, Sweaty Koul, Randall B Meacham, Fernando J Kim.   

Abstract

Renal cell carcinoma (RCC) is a disease in which cancer cells form in the tubules of the kidney. RCC, the incidence of which is increasing annually, represents five percent of adult epithelial cancers. Clear cell carcinoma represents the most frequent histological subtype. RCC is characterized by a lack of early warning signs, diverse clinical manifestations. Incidentally detected tumors in asymptomatic individuals have been steadily increasing owing to the increased usage of various imaging technologies. Currently there are no recommendations for screening to detect and make an early diagnosis of renal cancer. But in recent years, the discovery of new molecular and cytogenetic markers has led to the recognition and classification of several novel subtypes of RCC, and the introduction of molecular-targeted therapy for advanced-stage RCC. We performed a literature review using PubMed and discuss current knowledge of epidemiology, pathophysiology, evaluation, treatment, and future research directions of RCC.

Entities:  

Year:  2010        PMID: 21969126      PMCID: PMC3180049     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  112 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Renal cell carcinoma staging. American College of Radiology. ACR Appropriateness Criteria.

Authors:  P L Choyke; E S Amis; L R Bigongiari; E I Bluth; W H Bush; P Fritzsche; L Holder; J H Newhouse; C M Sandler; A J Segal; M I Resnick; E A Rutsky
Journal:  Radiology       Date:  2000-06       Impact factor: 11.105

Review 3.  The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.

Authors:  Daniel Cho; Sabina Signoretti; Meredith Regan; James W Mier; Michael B Atkins
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

Review 4.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 5.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

6.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

Review 7.  Prognostic factors in renal carcinoma.

Authors:  B I Rini; N J Vogelzang
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

Review 8.  Prognostic factors in renal cancer.

Authors:  J B Thrasher; D F Paulson
Journal:  Urol Clin North Am       Date:  1993-05       Impact factor: 2.241

9.  Staging of 119 patients with renal cell carcinoma: the yield and cost-effectiveness of pelvic CT.

Authors:  J R Fielding; N Aliabadi; A A Renshaw; S G Silverman
Journal:  AJR Am J Roentgenol       Date:  1999-01       Impact factor: 3.959

Review 10.  Vitamin K-dependent actions of Gas6.

Authors:  Lola Bellido-Martín; Pablo García de Frutos
Journal:  Vitam Horm       Date:  2008       Impact factor: 3.421

View more
  52 in total

1.  A Multimodal and Pathological Analysis of a Renal Cell Carcinoma Metastasis to the Thyroid Gland 11 Years Post Nephrectomy.

Authors:  Thomas Rand Geisbush; Zaneta Dymon; Medhat Sam Gabriel; Vivek Yedavalli
Journal:  J Radiol Case Rep       Date:  2019-04-30

Review 2.  Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

Authors:  Luís León; Roberto García-Figueiras; Roberto García-Figueras; Cristina Suárez; Antonia Arjonilla; Javier Puente; Blanca Vargas; Maria José Méndez Vidal; Carmen Sebastiá
Journal:  Target Oncol       Date:  2013-12-12       Impact factor: 4.493

3.  Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM.

Authors:  Junyi Jiang; Xu Chen; Hao Liu; Jing Shao; Ruihui Xie; Peng Gu; Chaohui Duan
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

4.  In vivo growth and responses to treatment of renal cell carcinoma in different environments.

Authors:  Yahya Alhamhoom; Guisheng Zhang; Mingming Gao; Houjian Cai; Dexi Liu
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 5.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

6.  Isolated thyroid metastasis from renal cell carcinoma.

Authors:  Ali Solmaz; Ali Muhammedoğlu; Serdar Altınay; Candaş Erçetin; Erkan Yavuz; Osman Bilgin Gülçiçek; Şenay Yalçın; Yeşim Erbil
Journal:  Turk J Surg       Date:  2015-07-06

Review 7.  Renal Cell Carcinoma: Molecular Aspects.

Authors:  Aman Kumar; Niti Kumari; Vinny Gupta; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2017-11-13

8.  The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling.

Authors:  Wei-Choong Ch'ng; Eric J Stanbridge; Khatijah Yusoff; Norazizah Shafee
Journal:  J Interferon Cytokine Res       Date:  2013-03-18       Impact factor: 2.607

9.  microRNA-451 inhibited cell proliferation, migration and invasion through regulation of MIF in renal cell carcinoma.

Authors:  Yan Tang; Wei Wan; Lijuan Wang; Shishun Ji; Juanjuan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

10.  MiR-216a exerts tumor-suppressing functions in renal cell carcinoma by targeting TLR4.

Authors:  Wanhui Wang; Enyang Zhao; Yang Yu; Bo Geng; Wenfu Zhang; Xuedong Li
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.